Socio-Clinical Factors Associated with Parkinson’s Disease Related Specific Self-Management Behaviors: The Role of Non-Motor Symptoms
Objective: To test associations between socio-clinical factors, self-management and patient activation among patients with Parkinson’s disease (PD), and to develop a predictive model for engagement…Genome-wide meta-analysis of Parkinson’s disease identifies a novel chromosomal 22 locus: findings from the COURAGE-PD consortium
Objective: The present study aims to conduct a meta-analysis in a large, diverse cohort to discover novel Parkinson’s disease (PD) loci and replicate previously reported…Statin use and incidence of Parkinson’s disease in women from the French E3N cohort study
Objective: To examine whether incident statin use is associated with lower Parkinson’s disease (PD) incidence while considering the potential for reverse causation. Background: Drug repurposing…Clinical effectiveness and economic impact of transcutaneous afferent patterned stimulation therapy for essential tremor in a real-world setting: protocol for a pragmatic trial
Objective: To determine the feasibility of delivery, clinical effectiveness, healthcare resource utilization (HCRU) and costs of transcutaneous afferent patterned stimulation (TAPS) therapy for the treatment…Sex Differences for Tau Association with Cognition in Early Parkinson’s Disease
Objective: To assess sex differences for cerebrospinal fluid (CSF) phosphorylated tau (p-tau) association with cognition in Parkinson’s disease (PD) Background: Tau biomarkers can predict cognitive…Lewy body disease clinical subgroups present similar disease progression rates
Objective: To characterize LBD clinical subgroups and identify possible differences in disease progression. Background: Patients with Lewy body disease (LBD) present a wide variety of…LIG1 polymorphism modifies the age at onset in patients with Spinocerebellar Ataxia type 2
Objective: Assessing the role of LIG1 Exon 6 A→C polymorphism acting as a modifier of clinical severity in patients with Spinocerebellar ataxia type 2 (SCA2).…Time-to-event approach mitigates the treatment masking effect of symptomatics on MDS-UPDRS Part III
Objective: To assess whether a time-to-event (TTE) approach may mitigate the masking effect of changing symptomatic therapy on Movement Disorders Society–Unified Parkinson’s Disease (PD) Rating…Local Field Potential Recordings in Parkinson’s Disease at Home: A Case Series Report
Objective: To report novel, real-world use of chronic local field potential (LFP) sensing in patients with Parkinson’s disease (PD) outside-of-clinic settings. Background: Recent advancements in…ADS024 attenuates striatal dopamine loss and restores movement in animal models of Parkinson’s disease
Objective: To evaluate the effect of ADS024, an oral single strain live biotherapeutic product (SS-LBP), on the pathophysiology of MPTP-induced Parkinson’s Disease (PD) phenotypes in…
- « Previous Page
- 1
- …
- 76
- 77
- 78
- 79
- 80
- …
- 153
- Next Page »